Emerging therapies for acute traumatic spinal cord injury

CMAJ. Canadian Medical Association Journal

Volumn 185, Issue 6, 2013, Pages 485-492

  Wilson, Jefferson R ^a   Forgione, Nicole ^a   Fehlings, Michael G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS; CETHRIN; CHONDROITIN ABC LYASE; FIBROBLAST GROWTH FACTOR 2; GM 1; MAGNESIUM POLYETHYLENE GLYCOL; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MINOCYCLINE; NALOXONE; NEUROPROTECTIVE AGENT; NEUROREGENERATIVE AGENT; NIMODIPINE; NOGO INHIBITOR; PLACEBO; RHO INHIBITOR; RILUZOLE; TIRILAZAD; UNCLASSIFIED DRUG;

BONE MARROW TRANSPLANTATION; CELL TRANSPLANTATION; CLINICAL RESEARCH; CONTINUOUS INFUSION; DECOMPRESSION SURGERY; DRUG MEGADOSE; EMBRYONIC STEM CELL; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOTHERMIA; MACROPHAGE; NEURAL STEM CELL; OLFACTORY ENSHEATHING CELL; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGENERATIVE MEDICINE; REVIEW; SCHWANN CELL; SPINAL CORD INJURY; STEM CELL TRANSPLANTATION; WOUND INFECTION;

EID: 84876857783     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.121206     Document Type: Review

References (52)

1. Noonan VK, Fingas M, Farry A, et al. The incidence and prevalence of spinal cord injury in Canada: a national perspective. Neuroepidemiology 2012;38:219-26.
2. Farry A, Baxter D. The incidence and prevalence of spinal cord injury in Canada: overview and estimates based on current evidence. Vancouver (BC): Rick Hansen Institute and Urban Futures; 2010. Available: www.urbanfutures.com/ reports/Report %2080.pdf (accessed 2011 June 15).
3. Tator CH, Fehlings MG. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 1991;75:15-26.
4. Schwartz G, Fehlings M. Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res 2002;137:177-90.
5. Fitch MT, Silver J. CNS injury, glial scars, and inflammation: inhibitory extracellular matrices and regeneration failure. Exp Neurol 2008;209:294-301.
6. Fehlings MG, Theodore N, Harrop J, et al. A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma 2011;28:787-96.
7. Wilson JR, Fehlings MG. Emerging approaches to the surgical management of acute traumatic Spinal Cord Injury. Neurotherapeutics 2011;8:187-94.
8. Chesnut RM, Marshall L, Klauber M, et al. The role of secondary brain injury in determining outcome from severe head injury. J Trauma 1993;34:216-22.
9. Levi L, Wolf A, Belzber H. Hemodynamic parameters in patients with acute cervical cord trauma: description, intervention, and prediction of outcome. Neurosurgery 1993;33:1007-10167.
10. Blood pressure management after acute spinal cord injury. Neurosurgery 2002;50:S58-62.
11. Management of acute spinal cord injuries in an intensive care unit or other monitored setting. Neurosurgery 2002; (Suppl 3): S51-7.
12. Furlan JC, Noonan V, Cadotte DW, et al. Timing of decompressive surgery of spinal cord after traumatic spinal cord injury: an evidence-based examination of pre-clinical and clinical studies. J Neurotrauma 2011;28:1371-99.
13. Bedbrook GM, Sedgley GI. The management of spinal injuries - past and present. Int Rehabil Med 1980;2:45-61.
14. Fehlings MG, Perrin RG. The timing of surgical intervention in the treatment of spinal cord injury: a systematic review of recent clinical evidence. Spine (Phila Pa 1976). 2006;31(Suppl 11):S28-35; discussion S6.
15. Fehlings MG, Vaccaro A, Wilson J, et al. Early versus delayed decompression for traumatic cervical spinal cord injury: results of the Surgical Timing in Acute Spinal Cord Injury Study (STASCIS). PLoS ONE 2012;7:e32037.
16. Fehlings MG, Rabin D, Sears W, et al. Current practice in the timing of surgical intervention in spinal cord injury. Spine 2010;35:S166-73.
17. Lo TP Jr, Cho KS, Garg MS, et al. Systemic hypothermia improves histological and functional outcome after cervical spinal cord contusion in rats. J Comp Neurol 2009;514:433-48.
18. Levi AD, Casella G, Green BA, et al. Clinical outcomes using modest intravascular hypothermia after acute cervical spinal cord injury. Neurosurgery 2010;66:670-7.
19. Bracken MB, Shepard M, Collins W, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990;322:1405-11.
20. Otani K, Abe H, Kadoya S. Beneficial effects of methylprednisolone sodium succinate in the treatment of acute spinal cord injury. Sekitsy Sekizui 1994;7:633-47.
21. Petijean ME, Pointillart V, Dixmerias F, et al. Medical treatment of spinal cord injury in the acute stage. Ann Fr Anesth Reanim 1998;17:115-22.
22. Bracken MB, Shepard M, Holford T, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997;277:1597-604.
23. Geisler FH, Coleman W, Grieco G, et al. The Sygen multicenter acute spinal cord injury study. Spine 2001;26:S87-98.
24. Braughler JM, Hall E. Effects of multi-dose methylprednisolone sodium succinate administration on injured cat spinal cord neurofilament degradation and energy metabolism. J Neurosurg 1984;61:290-5.
25. Bracken MB. Steroids for acute spinal cord injury. Cochrane Database Syst Rev 2012;1:CD001046.
26. Hurlbert RJ. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg 2000;93:1-7.
27. Hugenholtz H, Cass D, Dvorak M. High-dose methylprednisilone for acute closed spinal cord injury - only a treatment option. Can J Neurol Sci 2002;3:227-35.
28. Baskin DS, Simpson RK Jr, Browning JL, et al. The effect of long-term high-dose naloxone infusion in experimental blunt spinal cord injury. J Spinal Disord 1993;6:38-43.
29. Fehlings MG, Tator CH, Linden RD. The effect of nimodipine and dextran on axonal function and blood flow following experimental spinal cord injury. J Neurosurg 1989;71:403-16.
30. Bose B, Osterholm J, Kalia M. Ganglioside-induced regeneration and reestablishment of axonal continuity in spinal cord - transected rats. Neurosci Lett 1986;63:165-9.
31. Miller RG, Mitchell JD, Lyon M. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007; (1): CD001447.
32. Fehlings MG, Wilson JR, Frankowski RF, et al. Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I Clinical Trial. J Neurosurg Spine 2012;17:151-6.
33. Grossman RG, Fehlings MG, Frankowski RF, et al., editors. A phase I multicenter trial to investigate the safety and pharmacokinetics profle of riluzole in the treatment of traumatic spinal cord injury. Proceedings of the Society for Neuroscience 12 meeting; 2012 Oct. 14; New Orleans.
34. Festoff BW, Ameenuddin S, Arnold PM, et al. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem 2006;97:1314-26.
35. Casha S, Zygun D, McGowan M, et al. Results of a phase II placebo-controlled randomized trial of minocylcine in acute spinal cord injury. Brain 2012;135:1224-36.
36. Teng YD, Mocchetti I, Taveira-DaSilva AM, et al. Basic fibroblast growth factor increases long-term survival of spinal motor neurons and improves respiratory function after experimental spinal cord injury. J Neurosci 1999;19:7037-47.
37. Spillmann AA, Bandtlow CE, Lottspeich F, et al. Identification and characterization of a bovine neurite growth inhibitor (bNI-220). J Biol Chem 1998;273:19283-93.
38. Freund P, Wannier T, Schmidlin E, et al. Anti-Nogo-A antibody treatment enhances sprouting of corticospinal axons rostral to a unilateral cervical spinal cord lesion in adult macaque monkey. J Comp Neurol 2007;502:644-59.
39. Sahni V, Kessler JA. Stem cell therapies for spinal cord injury. Nat Rev Neurol 2010;6:363-72.
40. Geffner LF, Santacruz P, Izurieta M, et al. Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies. Cell Transplant 2008;17:1277-93.
41. Yoon SH, Shim YS, Park YH, et al. Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage-colony stimulating factor: phase I/II clinical trial. Stem Cells 2007;25:2066-73.
42. Syková E, Homola A, Mazanec R, et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant 2006;15:675-87.
43. Deda H, Inci MC, Kurekci AE, et al. Treatment of chronic spinal cord injured patients with autologous bone marrow-derived hema topoietic stem cell transplantation: 1-year follow-up. Cytotherapy 2008;10:565-74.
44. Mackay-Sim A, Feron F, Cochrane J, et al. Autologous olfactory ensheathing cell transplantation in human paraplegia: a 3-year clinical trial. Brain 2008;131:2376-86.
45. Lima C, Escada P, Pratas-Vital J, et al. Olfactory mucosal autografts and rehabilitation for chronic traumatic spinal cord injury. Neurorehabil Neural Repair 2010;24:10-22.
46. Saberi H, Moshayedi P, Aghayan HR, et al. Treatment of chronic thoracic spinal cord injury patients with autologous Schwann cell transplantation: an interim report on safety considerations and possible outcomes. Neurosci Lett 2008;443:46-50.
47. Knoller N, Auerbach G, Fulga V, et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J Neurosurg Spine 2005;3:173-81.
48. Lammertse D P, Jones LA, Charlifue SB, et al. Autologous incubated macrophage therapy in acute, complete spinal cord injury: results of the phase 2 randomized controlled multicenter trial. Spinal Cord 2012;50:661-71.
49. Bradbury EJ, Carter LM. Manipulating the glial scar: chondroitin ase ABC as a therapy for spinal cord injury. Brain Res Bull 2011;84:306-16.
50. Luo J, Borgens R, Shi R. Polyethylene glycol immediately repairs neuronal membranes and inhibits free radical production after acute spinal cord injury. J Neurochem 2002;83:471-80.
51. Das M, Patil S, Bhargava N, et al. Auto-catalytic ceria nanoparticles offer neuroprotection to adult rat spinal cord neurons. Biomaterials 2007;28:1918-25.
52. Harkema S, Gerasimenko Y, Hodes J, et al. Effect of epidural stimulation of the lumbosacral spinal cord on voluntary movement, standing, and assisted stepping after motor complete paraplegia: a case study. Lancet 2011;377:1938-47.